Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BPTH

Bio-Path Holdings Inc

Apr 16 • 10:03AM ET

2.97

Dollar change +0.03
Percentage change 1.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-35.71	Insider Own	0.25%	Shs Outstand	0.75M	Perf Week	-22.25%
Market Cap	2.23M	Forward P/E	-	EPS next Y	-18.41	Insider Trans	0.00%	Shs Float	0.75M	Perf Month	-35.43%
Income	-16.08M	PEG	-	EPS next Q	-4.54	Inst Own	84.35%	Short Float	8.99%	Perf Quarter	-67.72%
Sales	0.00M	P/S	-	EPS this Y	44.37%	Inst Trans	-	Short Ratio	2.46	Perf Half Y	-80.20%
Book/sh	0.71	P/B	4.16	EPS next Y	1.60%	ROA	-167.56%	Short Interest	0.07M	Perf Year	-89.32%
Cash/sh	1.40	P/C	2.12	EPS next 5Y	-	ROE	-220.02%	52W Range	2.94 - 44.80	Perf YTD	-67.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.89%	ROI	-3564.97%	52W High	-93.37%	Beta	0.44
Dividend TTM	-	Quick Ratio	1.60	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.02%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	1.60	EPS Y/Y TTM	7.82%	Oper. Margin	0.00%	RSI (14)	25.34	Volatility	11.85% 14.07%
Employees	10	Debt/Eq	0.25	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	50.75%	Payout	-	Rel Volume	1.55	Prev Close	2.94
Sales Surprise	-	EPS Surprise	36.48%	Sales Q/Q	-	Earnings	Mar 08 BMO	Avg Volume	27.41K	Price	2.97
SMA20	-26.05%	SMA50	-49.80%	SMA200	-71.87%	Trades		Volume	5,841	Change	1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Initiated	ROTH Capital	Buy	$13
Nov-13-17	Reiterated	H.C. Wainwright	Buy	$4.50 → $1.50
Aug-10-16	Reiterated	Maxim Group	Buy	$5 → $2
Apr-18-16	Initiated	Rodman & Renshaw	Buy	$5
Jun-02-14	Resumed	Maxim Group	Buy	$5
May-09-14	Initiated	Maxim Group	Buy	$5

Apr-15-24 07:00AM	Bio-Path Holdings Expands Global Patent Portfolio (GlobeNewswire)
Apr-02-24 07:00AM	Bio-Path Holdings Provides 2024 Clinical and Operational Update (GlobeNewswire) -7.93%
Mar-27-24 04:43PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23 (Newsfile)
Mar-10-24 08:17AM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-08-24 10:45PM	Q4 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -6.42%
07:00AM	Loading…
07:00AM	Bio-Path Holdings Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 (GlobeNewswire)
Feb-21-24 07:00AM	Bio-Path Holdings Announces 1-for-20 Reverse Stock Split (GlobeNewswire)
Jan-10-24 07:00AM	Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients (GlobeNewswire) +5.64%
Dec-14-23 07:00AM	Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (GlobeNewswire)
Nov-20-23 12:54PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-15-23 07:12AM	Bio-Path: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-08-23 07:00AM	Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023 (GlobeNewswire) -7.78%
Oct-24-23 07:00AM	Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia (GlobeNewswire) +10.36%
04:01PM	Loading…
Sep-08-23 04:01PM	Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -5.10%
Aug-30-23 05:11PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23 (Newsfile)
Aug-15-23 10:04PM	Q2 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -11.66%
07:06AM	Bio-Path: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 07:00AM	Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023 (GlobeNewswire) +24.36%
Aug-03-23 08:22AM	Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire) -46.02%
Aug-01-23 07:00AM	Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (GlobeNewswire) -7.54%
Jul-17-23 07:00AM	Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors (GlobeNewswire)
Jun-02-23 04:49PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23 (Newsfile) -5.83%
May-18-23 12:41PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 09:13PM	Q1 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
07:06AM	Bio-Path: Q1 Earnings Snapshot (AP Finance)
07:00AM	Bio-Path Holdings Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 07:00AM	Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023 (GlobeNewswire) +8.63%
05:25PM	Loading…
Apr-10-23 05:25PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22 (Newsfile)
Apr-04-23 01:19PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 08:37AM	Market Sentiment Around Loss-Making Bio-Path Holdings, Inc. (NASDAQ:BPTH) (Simply Wall St.)
Mar-31-23 07:00AM	Bio-Path Holdings Reports Full Year 2022 Financial Results (GlobeNewswire) -18.71%
Mar-24-23 04:01PM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 (GlobeNewswire)
Mar-16-23 07:00AM	Bio-Path Holdings Provides Clinical and Operational Update (GlobeNewswire)
Dec-28-22 09:59AM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-07-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors (GlobeNewswire) -5.88%
Nov-15-22 07:00AM	Bio-Path Holdings Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-08-22 07:00AM	Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022 (GlobeNewswire) -7.80%
Nov-07-22 07:00AM	Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -45.96%
Oct-24-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients (GlobeNewswire)
Oct-23-22 09:36AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-30-22 11:24AM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) (Newsfile)
Sep-06-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:00AM	Bio-Path Holdings Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-09-22 07:00AM	Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022 (GlobeNewswire)
Jun-13-22 12:10PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
May-17-22 07:00AM	Bio-Path Holdings Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-16-22 07:51AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-10-22 07:00AM	Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022 (GlobeNewswire)
Apr-13-22 04:30PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH) (ACCESSWIRE) -17.02%
Apr-12-22 04:01PM	Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-06-22 07:00AM	Bio-Path Holdings Appoints Aline Sherwood to Board of Directors (GlobeNewswire)
Mar-11-22 07:00AM	Bio-Path Holdings Reports Full Year 2021 Financial Results (GlobeNewswire) -8.07%
Mar-08-22 04:30PM	Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-04-22 07:00AM	Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022 (GlobeNewswire)
Jan-05-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-13-21 07:00AM	Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting (GlobeNewswire) -7.94%
Dec-06-21 04:22AM	Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation (Simply Wall St.)
Nov-12-21 07:00AM	Bio-Path Holdings Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-05-21 08:00AM	Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021 (GlobeNewswire)
Nov-04-21 09:01AM	Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting (GlobeNewswire)
Oct-27-21 07:00AM	Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors (GlobeNewswire)
Sep-20-21 04:30PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH) (ACCESSWIRE)
Aug-25-21 10:24AM	Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug (Zacks) -10.86%
Aug-24-21 11:00AM	Why Bio-Path Holdings Shares Are Surging Higher Today (Benzinga) +14.94%
08:33AM	Bio-Path Stock Jumps as Leukemia Treatment Candidate Moves to Testing (TheStreet.com)
07:00AM	Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients (GlobeNewswire)
Aug-13-21 07:00AM	Bio-Path Holdings Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Aug-06-21 07:00AM	Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021 (GlobeNewswire)
Jun-22-21 07:00AM	Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 (GlobeNewswire) +9.39%
Jun-15-21 03:22PM	Is Bio-Path Holdings, Inc. (BPTH) A Good Stock To Buy? (Insider Monkey) -5.30%
Jun-09-21 01:56AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Can Afford To Drive Business Growth (Simply Wall St.)
May-27-21 08:00AM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
May-14-21 07:00AM	Bio-Path Holdings Reports First Quarter 2021 Financial Results (GlobeNewswire)
06:45AM	Bio-Path Holdings, Inc. to Host Earnings Call (ACCESSWIRE)
May-07-21 07:00AM	Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021 (GlobeNewswire)
Apr-26-21 09:00AM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
Apr-22-21 07:00AM	Bio-Path Announces Publication in Biomedicines (GlobeNewswire)
Apr-12-21 07:00AM	Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting (GlobeNewswire) -8.33%
Apr-05-21 08:03AM	Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study (Benzinga) +6.71%
07:00AM	Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia (GlobeNewswire)
Mar-11-21 07:00AM	Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting (GlobeNewswire) +15.26%
Mar-10-21 07:00AM	Bio-Path Holdings Reports Full Year 2020 Financial Results (GlobeNewswire) -6.40%
05:30AM	Bio-Path Holdings, Inc. to Host Earnings Call (ACCESSWIRE)
Mar-03-21 04:01PM	Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021 (GlobeNewswire)
Feb-18-21 04:01PM	Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock (GlobeNewswire) +9.63%
Feb-16-21 07:15AM	Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock (GlobeNewswire) -14.89%
Feb-13-21 07:00AM	Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-10-21 07:08AM	Bio-Path Quadruples on Receipt of Cancer-Drug Tech Patent (TheStreet.com) +126.35%
07:00AM	Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology (GlobeNewswire)
Dec-21-20 02:05PM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
Dec-11-20 03:48AM	We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate (Simply Wall St.) -8.76%
Nov-19-20 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002 (GlobeNewswire)
Nov-13-20 07:00AM	Bio-Path Holdings Reports Third Quarter 2020 Financial Results (GlobeNewswire) -6.69%
Nov-06-20 08:00AM	Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020 (GlobeNewswire)
Oct-22-20 07:00AM	Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers (GlobeNewswire) +28.61%
Sep-18-20 12:00PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
Sep-09-20 08:00AM	Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference (GlobeNewswire)

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BPTH

Bio-Path Holdings Inc

Upgrade your FINVIZ experience